Adhering to the principles of evidence-based medicine, Venus Medtech has consistently conducted long-term follow-up studies ...

Inc. (Stock Code: 2500.HK, hereinafter referred to as 'Venus Medtech' or the 'Company'), a global leader in structural heart therapies, has announced financial results for the year ended December 31, ...

The global flurry of innovation in tricuspid valve interventions continues in ... with other TTVR platforms like Cardiovalve, Intrepid, Topaz, and Trisol in development, as cited by Neil Fam ...

Key findings reported in the year include: Cardiovalve ... % severe or worse tricuspid regurgitation showed 90% reduced to ≤mild regurgitation at 30-day follow-up. VenusP-Valve (5-year CE ...